We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Eli Lilly, ConocoPhillips, PNC Financial Services, Equinix, and Freeport-McMoRan
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 2, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , ConocoPhillips (COP - Free Report) , The PNC Financial Services Group, Inc. (PNC - Free Report) , Equinix, Inc. (EQIX - Free Report) and Freeport-McMoRan Inc. (FCX - Free Report)
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Eli Lilly, ConocoPhillips and PNC Financial
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., ConocoPhillips, and The PNC Financial Services Group, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+59.6 % vs. +26.0%) on the back of Lilly's solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Lilly's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals.
It has an exciting pipeline of potential new medicines including tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both candidates have multibillion-dollar sales potential.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.
ConocoPhillips shares have modestly outperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (+96.1% vs. +89.5%). The company holds a bulk of acres in the unconventional plays of Eagle Ford shale, Permian Basin and Bakken shale. The Zacks analyst believes that significant opportunities are there for the firm in the Bakken Shale, where it owns about 750 undrilled locations that could provide access to huge reserves.
Notably, the company has revised its expected 2022 return of capital to shareholders upward to $10 billion, reflecting an increase from the prior-mentioned $8 billion. COP projects its 2022 production at 1.76 MMBoe/d, suggesting an improvement from 1.6 MMBoe/d reported last year. Also, the company's balance sheet is significantly less leveraged than the industry it belongs to. Its massive liquidity position will enable it to pay off the short-term debt of $1,160 million. Given these tailwinds, ConocoPhillips is considered a preferred energy firm to own now.
PNC shares have declined -8.0% over the past year against the Zacks Banks - Major Regional industry's decline of -12.4%. The Zacks analyst believes that mounting expenses will likely keep denting the bottom line in the near term. Though the Fed has hiked interest rates and signaled more hikes this year, the overall low interest rate environment might strain the bank's net interest margin (NIM) in the near term. The lack of diversification in the loan portfolio is concerning.
However, Economic growth and robust pipelines are expected to support loan and deposit balances, aiding its balance sheet. Planned investments in inorganic expansion strategies will strengthen its banking franchise and diversify its business mix. Sound capital deployment activities are other positives.
Other noteworthy reports we are featuring today include Equinix, Inc. and Freeport-McMoRan Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Eli Lilly, ConocoPhillips, PNC Financial Services, Equinix, and Freeport-McMoRan
For Immediate Release
Chicago, IL – June 2, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , ConocoPhillips (COP - Free Report) , The PNC Financial Services Group, Inc. (PNC - Free Report) , Equinix, Inc. (EQIX - Free Report) and Freeport-McMoRan Inc. (FCX - Free Report)
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Eli Lilly, ConocoPhillips and PNC Financial
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., ConocoPhillips, and The PNC Financial Services Group, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+59.6 % vs. +26.0%) on the back of Lilly's solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Lilly's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals.
It has an exciting pipeline of potential new medicines including tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both candidates have multibillion-dollar sales potential.
However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
ConocoPhillips shares have modestly outperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (+96.1% vs. +89.5%). The company holds a bulk of acres in the unconventional plays of Eagle Ford shale, Permian Basin and Bakken shale. The Zacks analyst believes that significant opportunities are there for the firm in the Bakken Shale, where it owns about 750 undrilled locations that could provide access to huge reserves.
Notably, the company has revised its expected 2022 return of capital to shareholders upward to $10 billion, reflecting an increase from the prior-mentioned $8 billion. COP projects its 2022 production at 1.76 MMBoe/d, suggesting an improvement from 1.6 MMBoe/d reported last year. Also, the company's balance sheet is significantly less leveraged than the industry it belongs to. Its massive liquidity position will enable it to pay off the short-term debt of $1,160 million. Given these tailwinds, ConocoPhillips is considered a preferred energy firm to own now.
(You can read the full research report ConocoPhillips here >>>)
PNC shares have declined -8.0% over the past year against the Zacks Banks - Major Regional industry's decline of -12.4%. The Zacks analyst believes that mounting expenses will likely keep denting the bottom line in the near term. Though the Fed has hiked interest rates and signaled more hikes this year, the overall low interest rate environment might strain the bank's net interest margin (NIM) in the near term. The lack of diversification in the loan portfolio is concerning.
However, Economic growth and robust pipelines are expected to support loan and deposit balances, aiding its balance sheet. Planned investments in inorganic expansion strategies will strengthen its banking franchise and diversify its business mix. Sound capital deployment activities are other positives.
(You can read the full research report on PNC here >>>)
Other noteworthy reports we are featuring today include Equinix, Inc. and Freeport-McMoRan Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.